Gallia G. Levy

机构：Spark Therapeutics (United States)

发表论文 67 篇 · 总被引 7206 次 · h-index 26

代表论文

• Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study (2022 · Haemophilia · 被引 36)
• A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A (2021 · The Journal of Clinical Pharmacology · 被引 12)
• Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3 (2022 · Research and Practice in Thrombosis and Haemostasis · 被引 11)
• Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011 (2022 · Blood · 被引 6)
• Research agenda and related workforce requirements inspired by Lived Experience Experts and grounded in health equity for the Bleeding Disorders Research Collaborative (2026 · Expert Review of Hematology · 被引 4)
• The Effects of Immunomodulation with Corticosteroids to Manage an AAV Capsid Immune response in the Phase I/II Study of SPK-8011 (2022 · Blood · 被引 1)